

Datasheet for ABIN7543066

Recombinant anti-CCR4 (Mogamulizumab Biosimilar) antibody[Go to Product page](#)

Overview

Quantity:	200 µg
Target:	CCR4 (Mogamulizumab Biosimilar)
Reactivity:	Human
Host:	Mouse
Antibody Type:	Recombinant Antibody
Clonality:	Chimeric
Conjugate:	This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated
Application:	Depletion (Dep)

Product Details

Purpose:	Anti-CCR4 [KW-0761 (Mogamulizumab)], Mouse IgG2a, kappa
Immunogen:	This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
Clone:	KW-0761
Isotype:	IgG2a kappa
Specificity:	This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
Characteristics:	Original Species of Ab: Human Original Format of Ab: IgG1
Purification:	Protein A affinity purified

Target Details

Target: CCR4 (Mogamulizumab Biosimilar)

Abstract: [CCR4 \(Mogamulizumab Biosimilar\) Products](#)

Target Type: Biosimilar

Background: CD194, CKR-4, CCR-4, CCR4, K5-5

UniProt: [P51679](#)

Application Details

Application Notes: The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.

Comment: This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C, -20 °C

Handling

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.